Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
28.50 p
1.00 p(4.17%)
At close: 4:00 PM EDT
28.50 p
1.00 p(4.17%)
Day’s Range― - ―
52-Week Range10.42 p - 29.90 p
Previous CloseN/A
Volume56.10K
Average Volume (3M)125.69K
Market Cap
£17.38M
Enterprise Value6.08 p
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Jul 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume139,941
30 Day Avg. Volume125,692
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.89M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Strong Gross MarginsRevenue growth and consistently high gross margins support RUA’s biomaterials and contract manufacturing model. This indicates valuable specialist capabilities and provides operating leverage if customer programs scale further.
Conservatively Levered Balance SheetLow leverage limits interest and refinancing pressure while preserving financial flexibility. The solid equity base gives RUA more capacity to fund development, absorb volatility and pursue growth without excessive debt dependence.
Core Manufacturing Profitability Is ImprovingThe shift toward profitable contract manufacturing and biomaterials licensing could create a more durable earnings base. Falling administrative costs and positive adjusted EBITDA suggest improving operating leverage, though delivery remains important.
Bears Say
Operating Profitability Remains UnprovenDespite improved results, RUA has not yet demonstrated consistent operating profitability. Continued losses can constrain reinvestment and make the business more dependent on successful execution of its commercial and cost-reduction plans.
Negative Operating And Free Cash FlowOngoing cash burn means the business is not yet self-funding, even though losses have narrowed. If commercial growth or the move to profitability is delayed, RUA may need external capital to sustain development and operations.
Spin-out And Commercialization Execution RiskThe spin-out strategy and early-stage platform opportunities may unlock greater long-term value, but they depend on development, funding and commercial execution. Delays or weak adoption could extend losses and defer expected benefits.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 29.90 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £17.38M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 19, 2027 which is in 315 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jun 30, 2026. The company reported -0.003 p earnings per share for the quarter.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of -0.003 p in its last earnings report. Following the earnings report the stock price went up 7.042%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―